Director, Supply Planning
Company: Vaxcyte Inc.
Location: San Carlos
Posted on: September 21, 2023
|
|
Job Description:
Company Profile:Vaxcyte, Inc. (Nasdaq: PCVX) is a vaccine
innovation company engineering high-fidelity vaccines to protect
humankind from the consequences of bacterial diseases. The Company
is developing broad-spectrum conjugate and novel protein vaccines
to prevent or treat bacterial infectious diseases. Vaxcyte's lead
candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal
conjugate vaccine being developed for the prevention of invasive
pneumococcal disease (IPD). The Company is re-engineering the way
highly complex immunizations are made through modern synthetic
techniques, including advanced chemistry and our exclusively
licensed XpressCFTM cell-free protein synthesis platform. Unlike
conventional cell-based approaches, the Company's system for
producing difficult-to-make proteins and antigens is intended to
accelerate its ability to efficiently create and deliver
high-fidelity vaccines with enhanced immunological benefits.
Vaxcyte's pipeline also includes VAX-XP, a PCV with an expanded
breadth of coverage of greater than 30 strains; VAX-A1, a
prophylactic vaccine candidate designed to prevent Group A Strep
infections; and VAX-PG, a therapeutic vaccine candidate designed to
slow or stop the progression of periodontal disease. The Company is
driven to eradicate or treat invasive bacterial infections, which
have serious and costly health consequences when left unchecked.
For more information, visit .Vaxcyte, headquartered in San Carlos,
CA, went public in June 2020 and currently has a team of
approximately 150 employees and anticipates continued, significant
growth. Following the October 2022 follow-on equity offering, which
generated approximately $651 million in net proceeds, the Company's
balance sheet is further strengthened to advance its pipeline of
novel vaccines, including VAX-24. On October 24, 2022, the Company
announced positive topline safety, tolerability and immunogenicity
data from the Phase 1/2 proof-of-concept study evaluating VAX-24 in
adults aged 18-64. The Company believes these results support a
best-in-class potential for VAX-24, which was designed to replace
the current standard-of-care in adults and children. VAX-24 is
being investigated for the prevention of IPD, which can be most
serious for infants, young children, older adults and those with
immune deficiencies or certain chronic health conditions. Given the
global impact of pneumococcal disease remains significant, the
public health community continues to advocate for vaccines that can
offer broader protection to prevent IPD. Vaxcyte's PCV franchise,
consisting of VAX-24 and VAX-XP, is designed specifically to
address this need and has the potential to deliver the broadest
protection for this very serious disease. We believe that our PCVs
could receive regulatory approval based on successful completion of
clinical studies utilizing well-defined surrogate immune endpoints,
consistent with how other PCVs have obtained regulatory approval in
the past, rather than requiring clinical field efficacy
studies.Summary:This role leads the supply planning team and has
overall responsibility to ensure we have enough inventory to
fulfill demand while minimizing write-offs due to product expiry.
Role will have direct reports and be responsible for clinical and
commercial products.Essential Functions:
#J-18808-Ljbffr
Keywords: Vaxcyte Inc., San Francisco , Director, Supply Planning, Executive , San Carlos, California
Click
here to apply!
|